(LNTH) Lantheus Holdings - Ratings and Ratios
Heart Ultrasound, Radiopharmaceuticals, Prostate Imaging, Cancer Therapies
LNTH EPS (Earnings per Share)
LNTH Revenue
Description: LNTH Lantheus Holdings
Lantheus Holdings, Inc. is a healthcare company that specializes in developing, manufacturing, and commercializing diagnostic and therapeutic products for various diseases, including heart disease, cancer, and others. The companys product portfolio includes a range of imaging agents and radiopharmaceuticals used in nuclear medicine and ultrasound procedures.
Key products include DEFINITY, an ultrasound enhancing agent, and PYLARIFY, a PET imaging agent for prostate cancer diagnosis. The company also offers TechneLite, a technetium generator, and Cardiolite, an imaging agent for assessing heart disease. Additionally, Lantheus has a pipeline of products in development, including 1095, a PSMA-targeted iodine-131-labeled small molecule, and PNT2002, a radiopharmaceutical therapy for metastatic castration-resistant prostate cancer.
From a financial perspective, Lantheus has a market capitalization of $5.625 billion and a price-to-earnings ratio of 23.17. The companys return on equity is 22.82%, indicating a strong ability to generate profits from shareholder equity. To further evaluate the companys performance, we can examine key performance indicators (KPIs) such as revenue growth, gross margin, and operating expenses. For instance, a high gross margin would indicate a strong pricing power and ability to maintain profitability.
Some relevant KPIs to monitor for Lantheus include: revenue growth rate, gross margin percentage, operating expense ratio, and research and development (R&D) expenditure as a percentage of revenue. These metrics can provide insights into the companys ability to drive growth, maintain profitability, and invest in new product development. For example, a high R&D expenditure as a percentage of revenue may indicate a strong commitment to innovation and future growth.
LNTH Stock Overview
| Market Cap in USD | 3,759m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 2015-06-25 |
LNTH Stock Ratings
| Growth Rating | -37.5% |
| Fundamental | 89.8% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -57.3% |
| Analyst Rating | 4.62 of 5 |
LNTH Dividends
Currently no dividends paidLNTH Growth Ratios
| Growth Correlation 3m | -86.2% |
| Growth Correlation 12m | -74.8% |
| Growth Correlation 5y | 79.8% |
| CAGR 5y | -12.79% |
| CAGR/Max DD 3y | -0.22 |
| CAGR/Mean DD 3y | -0.49 |
| Sharpe Ratio 12m | 0.99 |
| Alpha | -53.55 |
| Beta | 0.163 |
| Volatility | 59.36% |
| Current Volume | 842.6k |
| Average Volume 20d | 1123.8k |
| Stop Loss | 50.5 (-4.6%) |
| Signal | -1.20 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (271.0m TTM) > 0 and > 6% of Revenue (6% = 91.2m TTM) |
| FCFTA 0.22 (>2.0%) and ΔFCFTA 2.01pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 60.61% (prev 67.31%; Δ -6.69pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.25 (>3.0%) and CFO 527.5m > Net Income 271.0m (YES >=105%, WARN >=100%) |
| Net Debt (-80.1m) to EBITDA (457.3m) ratio: -0.18 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.29 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (70.3m) change vs 12m ago -0.41% (target <= -2.0% for YES) |
| Gross Margin 63.75% (prev 65.19%; Δ -1.44pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 74.98% (prev 74.13%; Δ 0.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 20.14 (EBITDA TTM 457.3m / Interest Expense TTM 19.7m) >= 6 (WARN >= 3) |
Altman Z'' 5.75
| (A) 0.44 = (Total Current Assets 1.20b - Total Current Liabilities 280.1m) / Total Assets 2.12b |
| (B) 0.28 = Retained Earnings (Balance) 597.6m / Total Assets 2.12b |
| (C) 0.20 = EBIT TTM 396.1m / Avg Total Assets 2.03b |
| (D) 0.63 = Book Value of Equity 596.9m / Total Liabilities 949.3m |
| Total Rating: 5.75 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 89.77
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 13.03% = 5.0 |
| 3. FCF Margin 31.12% = 7.50 |
| 4. Debt/Equity 0.49 = 2.38 |
| 5. Debt/Ebitda 1.24 = 1.40 |
| 6. ROIC - WACC 10.90% = 12.50 |
| 7. RoE 23.57% = 1.96 |
| 8. Rev. Trend 89.05% = 4.45 |
| 9. Rev. CAGR 18.09% = 2.26 |
| 10. EPS Trend 32.21% = 0.81 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of LNTH shares?
Over the past week, the price has changed by -3.31%, over one month by -1.78%, over three months by -33.94% and over the past year by -49.11%.
Is Lantheus Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LNTH is around 36.16 USD . This means that LNTH is currently overvalued and has a potential downside of -31.7%.
Is LNTH a buy, sell or hold?
- Strong Buy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LNTH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 88 | 66.2% |
| Analysts Target Price | 88 | 66.2% |
| ValueRay Target Price | 39.4 | -25.7% |
Last update: 2025-09-04 04:42
LNTH Fundamental Data Overview
CCE Cash And Equivalents = 695.6m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 14.7048
P/E Forward = 9.1075
P/S = 2.4722
P/B = 3.222
P/EG = 0.61
Beta = 0.138
Revenue TTM = 1.52b USD
EBIT TTM = 396.1m USD
EBITDA TTM = 457.3m USD
Long Term Debt = 566.8m USD (from longTermDebt, last quarter)
Short Term Debt = 796.0k USD (from shortTermDebt, last quarter)
Debt = 567.6m USD (Calculated: Short Term 796.0k + Long Term 566.8m)
Net Debt = -80.1m USD (from netDebt column, last quarter)
Enterprise Value = 3.63b USD (3.76b + Debt 567.6m - CCE 695.6m)
Interest Coverage Ratio = 20.14 (Ebit TTM 396.1m / Interest Expense TTM 19.7m)
FCF Yield = 13.03% (FCF TTM 473.2m / Enterprise Value 3.63b)
FCF Margin = 31.12% (FCF TTM 473.2m / Revenue TTM 1.52b)
Net Margin = 17.82% (Net Income TTM 271.0m / Revenue TTM 1.52b)
Gross Margin = 63.75% ((Revenue TTM 1.52b - Cost of Revenue TTM 551.3m) / Revenue TTM)
Tobins Q-Ratio = 6.08 (Enterprise Value 3.63b / Book Value Of Equity 596.9m)
Interest Expense / Debt = 0.87% (Interest Expense 4.92m / Debt 567.6m)
Taxrate = 27.50% (118.5m / 431.0m)
NOPAT = 287.1m (EBIT 396.1m * (1 - 27.50%))
Current Ratio = 4.29 (Total Current Assets 1.20b / Total Current Liabilities 280.1m)
Debt / Equity = 0.49 (Debt 567.6m / last Quarter total Stockholder Equity 1.17b)
Debt / EBITDA = 1.24 (Net Debt -80.1m / EBITDA 457.3m)
Debt / FCF = 1.20 (Debt 567.6m / FCF TTM 473.2m)
Total Stockholder Equity = 1.15b (last 4 quarters mean)
RoA = 12.81% (Net Income 271.0m, Total Assets 2.12b )
RoE = 23.57% (Net Income TTM 271.0m / Total Stockholder Equity 1.15b)
RoCE = 23.07% (Ebit 396.1m / (Equity 1.15b + L.T.Debt 566.8m))
RoIC = 16.73% (NOPAT 287.1m / Invested Capital 1.72b)
WACC = 5.83% (E(3.76b)/V(4.33b) * Re(6.62%)) + (D(567.6m)/V(4.33b) * Rd(0.87%) * (1-Tc(0.28)))
Shares Correlation 3-Years: 24.24 | Cagr: -0.10%
Discount Rate = 6.62% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈441.9m ; Y1≈545.1m ; Y5≈930.0m
Fair Price DCF = 232.6 (DCF Value 15.82b / Shares Outstanding 68.0m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 89.05 | Revenue CAGR: 18.09%
Rev Growth-of-Growth: -19.52
EPS Correlation: 32.21 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -133.8
Additional Sources for LNTH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle